An association between IDH status and amino acid PET parameters has been recently reported in LGG, as the IDH-1/2 wild-type lesions have greater metabolic activity than IDH1/2 mutated lower-grade gliomas in terms of the SUVmax and SUV ratio [60], even if these results need confirmation in larger studies. This evidence concerns the gene IDH1 and central nervous system cancer.